Stéphane Bancel, Founding CEO at Moderna, shared an update from Moderna, on LinkedIn, adding:
“Today is an important milestone for Moderna.
In 2020, mRNA helped change what was possible in infectious disease, as our teams worked to deliver a COVID-19 vaccine at unprecedented speed, in less than a year.
Today, we announced that our Phase 3 study of intismeran autogene, our individualized neoantigen therapy, in combination with KEYTRUDA met both its primary Recurrence Free Survival (RFS) endpoint and key secondary Distant Metastasis-Free Survival (DMFS) endpoint in melanoma.
We will share the detailed clinical data at an upcoming international medical conference.
But today, I am grateful to the patients and families who participated in this Phase 3 study, to our colleagues at Merck, and to the Moderna teams who have worked for 10 years toward this moment.
Our ambition has always been bigger than any one medicine: to use mRNA to create many families, or modalities, of new innovative medicines for patients.
From infectious disease to cancer, we are still at the beginning of what may be possible with mRNA science to help improve people’s lives.
Proud of the progress. Humbled by the responsibility. Optimistic about what comes next.”
Quoting Moderna:
“Moderna and Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
This also can be interesting: INTerpath-001 Trial: Personalized mRNA Cancer Vaccine for Melanoma
